Moderna has appointed Ester Banque as its new chief commercial officer to lead the company through several upcoming product launches [1].
The leadership change signals Moderna's transition from a company primarily known for a single COVID-19 vaccine to a diversified pharmaceutical player. By installing a veteran executive to manage commercial operations, the company aims to scale its market presence as it moves toward a broader portfolio of mRNA-based medicines.
Banque previously served as a senior executive at Zoetis and Bristol Myers Squibb [1]. Her appointment comes alongside a restructuring of internal responsibilities, which includes an expanded role for President Stephen Hoge [2].
These organizational shifts are designed to position the company for the rollout of up to three new products [3]. These launches are slated for the period between 2027 and 2028 [4].
The anticipated pipeline includes a seasonal flu vaccine, and a norovirus vaccine [5]. Additionally, Moderna plans to launch a combination shot targeting both flu and COVID-19 [5].
The company is headquartered in Cambridge, Massachusetts [6]. The leadership updates were announced on June 16, 2024 [6].
“Moderna has appointed Ester Banque as its new chief commercial officer”
This restructuring indicates that Moderna is shifting its focus from pandemic response to long-term commercial sustainability. By hiring a CCO with experience from established firms like Bristol Myers Squibb, Moderna is building the infrastructure necessary to compete in the crowded seasonal respiratory vaccine market and expanding into non-COVID indications.
